Retatrutide has produced some of the largest weight loss figures ever reported in obesity trials. It also has no price, no formulary placement, no copay, and no legal way to obtain it by prescription, and that will remain true well into next year.
Eli Lilly said it plans to submit a Biologics License Application to the FDA in the first quarter of 2027, pushing back a timeline the company had previously indicated could arrive before the end of 2026. Lilly attributed the delay to the additional time needed to assemble and validate manufacturing and quality-control data that regulators must review.
